Quantum company IonQ has announced an investment partnership with the Centre for Commercialization of Regenerative Medicine (CCRM) to accelerate next-generation therapeutic development using hybrid quantum and quantum-AI technologies.
The partnership includes an investment commitment into CCRM’s new quantum-biotech initiatives and establishes IonQ as the core technology partner across CCRM’s global network of advanced therapy hubs.
With more than 100,000 square feet of good manufacturing practice (GMP) facilities, more than 300 scientific staff and a global network of academic and industry partners, CCRM is one of the world’s leading accelerators for advanced therapies. CCRM was established in 2011 in Toronto, Canada, to realise the promise of regenerative medicine and deliver durable treatments, and even cures, for the world’s most debilitating chronic diseases. CCRM’s global network of academic researchers, industry partners, and investors will work closely with IonQ to provide computational advantages to its members.
“IonQ’s quantum technologies are poised to reshape industries, and health care is one of the most exciting frontiers,” said Niccolo de Masi, chairman and CEO of IonQ.
“Together with CCRM and its global partners, we will identify, test, and deploy breakthrough applications that will transform therapeutic development, biomanufacturing, and delivery for patients across the globe.”
The collaboration will initially focus on areas including bioprocess optimization, disease-modelling workflows, and quantum enhanced simulation to support the design and manufacturing of advanced therapies. The partnership aims to address some of the most pressing challenges in health care and life sciences. Initial projects will be launched in both Canada and Sweden in 2026.
Michael May, president and CEO of CCRM, said: “By combining our strengths we are uniquely positioned to unlock solutions that were previously beyond reach. Just as CCRM focused on biomanufacturing 15 years ago, this frontier-of-science collaboration will help accelerate the discovery and application of advanced therapies, with the potential to make a real difference for patients worldwide. We are very excited by this opportunity and collaboration with IonQ.”
“Like Canada, Sweden has identified advanced therapies and quantum computing as areas of high priority for development and commercialization,” says Fredrik Wessberg, CEO of CCRM Nordic.
“This partnership will help demonstrate the value of the CCRM network of hubs, and the need for global collaboration to deliver complex health care modalities to patients globally.”
The announcement builds on IonQ’s recent collaboration with AstraZeneca to establish a new quantum application development centre in Sweden within AstraZeneca’s BioVenture Hub. Earlier this year, IonQ announced that with the acquisition of Oxford Ionics it would expand R&D and quantum engineering teams in Oxford. IonQ also established a long-term partnership with Einride in Stockholm, Sweden in April 2025. In 2024, IonQ established its first European Innovation Center at QuantumBasel in Switzerland, and the company completed its acquisition of Switzerland-based IDQ.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.